Liaqat Khan

Liaqat Khan

Auto-generated profile, based on publicly available information

Liaqat Khan

Research Center, Benazir Bhutto Hospital of Rawalpindi Medical University, Rawalpindi, Pakistan

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2024 in Journal of the National Cancer Center
Verified
Journal Article
Open access
YDYi Dong
Yi Dong
LKLiaqat Khan
Liaqat Khan
YYYi Yao
Yi Yao
Immune checkpoint inhibitors (ICIs) have significantly improved outcomes for patients with advanced driver-negative non-small cell lung cancer (NSCLC). However, targeted therapy remains the preferred treatment for advanced driver-positive NSCLC, including cases with epidermal growth factor receptor (EGFR) mutations. Considering the variability in EGFR-mutant NSCLC, including expression levels of programmed cell death ligand 1 (PD-L1), tumor mutation burden (TMB), and other immunological features, the application of immunotherapy in this group is still a subject of investigation. Therefore, we have summarized and analyzed the immunological characteristics and regulatory mechanisms of different EGFR mutations in NSCLC, as well as the current clinical application of immunotherapy in the EGFR-mutant population, to provide a reference for future research.